Abstract
Extrapolation of animal data to assess pharmacokinetic parameters in humans is an important tool in drug development. Allometric scaling has many proponents, and many different approaches and techniques have been proposed to optimise the prediction of pharmacokinetic parameters from animals to humans. The allometric approach is based on the power function Y = aWb, where the bodyweight of the species is plotted against the pharmacokinetic parameter of interest on a log-log scale. Clearance, volume of distribution and elimination half-life are the 3 most frequently extrapolated pharmacokinetic parameters.
Clearance is not predicted very well (error between predicted and observed clearance >30%) using the basic allometric equation in most cases. Thus, several other approaches have been proposed. An early approach was the concept of neoteny, where the clearance is predicted on the basis of species bodyweight and maximum life-span potential. A second approach uses a 2-term power equation based on brain and bodyweight to predict the intrinsic clearance of drugs that are primarily eliminated by phase I oxidative metabolism. Most recently, the use of the product of brain weight and clearance has been proposed. A literature review reveals different degrees of success of improved prediction with the different methods for various drugs. In a comparative study, the determining factor in selecting a method for prediction of clearance was found to be the value of the exponent. Integration of in vitro data into in vivo clearance to improve the predictive performance of clearance has also been suggested. Although there are proponents of using body surface area instead of bodyweight, no advantage has been noted in this approach. It has also been noted that the unbound clearance of a drug cannot be predicted any better than the total body clearance (CL).
In general, there is a good correlation between bodyweight and volume of the central compartment (Vc); hence, Vc does not face the same complications as CL.
The relationship between elimination half-life (t1/2β) and bodyweight across species results in poor correlation, most probably because of the hybrid nature of this parameter. When a reasonable prediction of CL and Vc is made, t1/2β may be predicted from the equation t1/2β = 0.693Vc/CL.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Mordenti J. Man versus beast. J Pharm Sci 1986; 75: 1028–40.
Dedrick RL. Animal scale-up. J Pharmacokinet Biopharm 1973; 1: 435–61.
Bischoff KB. Some fundamental considerations of the applications of pharmacokinetics to cancer chemotherapy. Cancer Chemother Rep 1975; 59: 777–93.
Sugita O, Sawada Y, Sugiyama Y, et al. Physiologically based pharmacokinetics of drug-drug interaction: a study of tolbu-tamide-sulfonamide interaction in rats. J Pharmacokinet Biopharm 1982; 10: 297–316.
Lin H, Sugiyama Y, Awazu S, et al. Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J Pharmacokinet Biopharm 1982; 10: 649–61.
King FG, Dedrick RL, Farris FF. Physiological pharmacokinetic modeling of cis-dichlorodiammineplatinum (II) (DDP) in several species. J Pharmacokinet Biopharm 1986; 14: 131–55.
Boxenbaum H. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 1984; 15: 1071–121.
Boxenbaum H. Interspecies scaling, allometry, physiological time and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 1982; 10: 201–27.
McNamara PG. Interspecies scaling in pharmacokinetics. In: Welling PG, Tse FLS, Dighe SV, editors. Pharmaceutical bioequivalence. New York: Mercel Dekker Inc, 1991.
Sacher G. Relation of lifespan to brain weight and body weight in mammals. In: Wolstenholme GEW, O’Connor M, editors. CIBA Foundation colloquia on aging. London: Churchill, 1959.
Boxenbaum H, Fertig JB. Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species. Eur J Drug Metab Pharmacokinet 1984; 9: 177–83.
Mahmood I, Balian JD. Interspecies scaling: Predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. J Pharm Sci 1996; 85: 411–4.
Mahmood I, Balian JD. Interspecies scaling: predicting clearance of drugs in humans: three different approaches. Xenobiotica 1996; 26: 887–95.
Houston B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 1469–79.
Lave TH, Dupin S, Schmitt C, et al. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: Application to 10 extensively metabolized drugs. J Pharm Sci 1997; 86: 584–90.
Chappel WR, Mordenti J. Extrapolation of toxicological and pharmacological data from animals to humans. Adv Drug Res 1991; 20: 1–116.
Voisin EM, Ruthsatz M, Collins JM, et al. Extrapolation of animal toxicity to humans: Interspecies comparisons in drug development. Regulatory Toxicol Pharmacol 1990; 12: 107–16.
Mahmood I. Interspecies scaling: predicting clearance of anticancer drugs in humans. A comparative study of three different approaches using body weight or body surface area. Eur J Drug Metab Pharmacokinet 1997; 21: 275–8.
McGovern PJ, Williams MG, Stewart JC. Interspecies comparison of acivicin pharmacokinetics. Drug Metab Dispos 1988; 16: 18–22.
Paxton JW, Kim SN, Whitfield LR. Pharmacokinetic and toxicity of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs and humans. Cancer Res 1990; 50: 2692–7.
Sangalli L, Bortollotti A, Jiritano L, et al. Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats and humans. Drug Metab Dispos 1988; 16: 749–53.
Dedrick RL, Forrester DD, Cannon JN, et al. Pharmacokinetics of 1-b-D-arabinofuranosylcytosine (Ara-C) deamination in several species. Biochem Phannacol 1973; 22: 2405–17.
Klotz U, Antonin KH, Bieck PR. Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. J Phannacol Exp Ther 1976; 199: 67–73.
Duthu GS. Interspecies correlation of the pharmacokinetics of erythromycin, oleandomycin, and tylosin. J Pharm Sci 1985; 74: 943–6.
EL Sayed MA, Loscher W, Frey HH. Pharmacokinetics of ethosuximide in the dog. Arch Int Pharmacodyn 1978; 234: 180–92.
Loscher W. Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse. J Pharmacol Exp Ther 1978; 204: 255–61.
Boxenbaum H. Comparative pharmacokinetics of benzodiazepines in dog and man. J Pharmacokinet Biopharm 1982; 10: 411–26.
Sawada Y, Hanano M, Sugiyama Y, et al. Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats. J Pharmacokinet Biopharm 1985; 13: 477–92.
Chiou WL, Hsu F-H. Correlation of unbound plasma clearances of fifteen extensively metabolized drugs between humans and rats. Pharm Res 1988; 10: 668–72.
Mahmood I, Balian JD. Interspecies scaling: a comparative study for the prediction of clearance and volume using two or more than two species. Life Sci 1996; 59: 579–85.
Bonati M, Latini R, Tognoni G. Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat, and mouse. Drug Metab Rev 1984–85; 15: 1355–83.
Mahmood I. Interspecies scaling: a comparative study of unbound vs total clearance. Does unbound clearance improve the predictive performance of allometric scaling? Eur J Drug Metab Pharmacokinet. In press.
Sawada Y, Hanano M, Sugiyama Y, et al. Prediction of the disposition of β-lactam antibiotics in humans from pharmacokinetic parameters in animals. J Pharmacokinet Biopharm 1984; 12: 241–61.
Tsunekawa Y, Hasegawa T, Nadai M, et al. Interspecies differences and scaling for the pharmacokinetics of xanthine derivatives. J Pharm Phannacol 1992; 44: 594–9.
Evans GH, Nies AS, Shand DG. The disposition of propranolol. III. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J Pharmacol Exp Ther 1973; 186: 114–22.
Widman M, Nilsson LB, Bryske B, et al. Disposition of remoxipride in different species: species differences in metabolism. Arzneimittel Forschung 1993; 43: 287–97.
Movin-Osswald G, Hammarlund-Udenaes M. Remoxipride: phannacokinetics and effect on plasma prolactin. Br J Clin Phannacol 1991; 32: 355–60.
Gascon RA, Calvo B, Hernandez RM, et al. Interspecies scaling of cimetidine-theophylline pharmacokinetic interaction: Interspecies scaling in phannacokinetic interaction. Pharm Res 1994; 11: 945–50.
Harvey PH, Clutton-Brock TH. Life history variation in primates. Evolution 1985; 39: 559–81.
Calder III WA, editor. Size, function, and life history. Cambridge (MA): Harvard University Press, 1984.
Bachmann K. Predicting toxicokinetic parameters in humans from toxicokinetic data acquired from three small mammalian species. J Appl Toxicol 1989; 9: 331–8.
Boxenbaum H, Ronfeld R. Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 1983; 245: R768–74.
Dedrick RL, Bischoff KB, Zaharko DZ. Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 1970; 54 Pt 1: 95–101.
Hutchaleelaha A, Chow H, Mayersohn M. Comparative phannacokinetics and interspecies scaling of amphotericin B in several mammalian species. J Phann Phannacol 1997; 49: 178–83.
Lave T, Saner A, Coassolo P, et al. Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor. J Pharm Phannacol 1996; 48: 573–7.
Mehta SC, Lu DR. Interspecies pharmacokinetic scaling of BSH in mice, rats, rabbits, and humans. Biopharm Drug Dispos 1995; 16: 735–44.
Boxenbaum H, Dilea C. First-time-in-human dose selection: allometric thoughts and perspectives. J Clin Pharmacol 1995; 35: 957–66.
Mahmood I. Integration of in-vitro data and brain weight in allometric scaling to predict clearance in humans: some suggestions. J Pharm Sci 1998; 87: 527–9.
Obach RS, Baxter JG, Liston TE, et al. The prediction of human phannacokinetic parameters from preclinical and in vitro metabolism. J Pharmacol Exp Ther 1997; 283: 46–58.
Matsui H, Yano K, Okuda T. Pharmacokinetics of cephalospo-rin SM-162 in mice, rats, rabbits, dogs, and rhesus monkeys. Antimicrob Agents Chemother 1982; 22: 213–7.
Nakagawa K, Koyama M, Matsui H, et al. Phannacokinetics of cefpiramide (SM-1652) in humans. Antimicrob Agents Chemother 1984; 25: 221–5.
Siefert HM, Maruhn D, Maul W, et al. Pharmacokinetics of ciprofloxacin. Arzheimittel Forschung 1986; 36: 1496–502.
Abadia AR, Aramayona JJ, Munoz MJ, et al. Disposition of ciprofloxacin following intravenous administration in dogs. J Vet Pharmacol Ther 1994; 17: 384–8.
Aramayona JJ, Mora J, Fraile LJ, et al. Penetration of enrofloxacin and ciprofloxacin into breast milk, and phannacokinetics of the drags in lactating rabbits and neonatal offspring. Am J Vet Res 1996; 57: 547–53.
Drusano GL, Plaisance KI, Forrest A, et al. Dose ranging study and constant infusion evaluation of ciprofloxacin. Antimicrob Agents Chemother 1986; 30: 440–3.
Lave T, Dupin S, Schmitt M, et al. Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransferase (COMT): use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans. Xenobiotica 1996; 26: 839–51.
Mahmood I. Interspecies scaling. Predicting volumes, mean residence time and elimination half-life: some suggestions. J Phann Phannacol 1998; 50: 493–9.
Campbell BD. Can allometric interspecies scaling be used to predict human kinetics? Drag Inform J 1994; 28: 235–45.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mahmood, I., Balian, J.D. The Pharmacokinetic Principles Behind Scaling from Preclinical Results to Phase I Protocols. Clin Pharmacokinet 36, 1–11 (1999). https://doi.org/10.2165/00003088-199936010-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199936010-00001